Pamela R. Soulos, MPH

home / authors / pamela-r-soulos-mph

Articles

Changes in Prostate Cancer Presentation for Radiation Oncology Care

Changes in Prostate Cancer Presentation for Radiation Oncology Care

Kevin W. Su, BS;Jane Hall, PhD;Rudi Ross, BS, CCRC;Pamela R. Soulos, MPH;Timothy D. Shafman, MD;James B. Yu, MD;Arie P. Dosoretz, MD;Daniel E. Dosoretz, MD;Steven E. Finkelstein, MD;Sharon Sa
October 3rd 2015

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Read More

Latest Updated Articles

Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: January 16th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
Published: January 6th 2025 | Updated: January 8th 2025
Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia
OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study